Macrophage-specific FGFR1 deletion alleviates high-fat-diet-induced liver inflammation by inhibiting the MAPKs/TNF

Yan-Ni Zhao1,2,3, Zhou-di Liu2, Tao Yan2

  • 1Joint Research Center on Medicine, The Affiliated Xiangshan Hospital of Wenzhou Medical University, Ningbo, 315700, China.

PubMed

Insights

Fibroblast growth factor receptor 1 (FGFR1) inhibition protects against non-alcoholic fatty liver disease (NAFLD) by reducing liver inflammation and fat accumulation. Targeting FGFR1 in macrophages offers a promising therapeutic strategy for NAFLD.

Area of Science:

  • Hepatology
  • Immunology
  • Metabolic Diseases

Background:

  • Non-alcoholic fatty liver disease (NAFLD) is linked to obesity-driven inflammation.
  • Macrophage activation and inflammation are key drivers in NAFLD progression.
  • Fibroblast growth factor receptor 1 (FGFR1) is implicated in macrophage activation.

Purpose of the Study:

  • To investigate the role of FGFR1 in the pathogenesis of NAFLD.
  • To determine if targeting FGFR1 can mitigate NAFLD progression.

Main Methods:

  • Utilized a high-fat diet (HFD) mouse model of NAFLD.
  • Examined p-FGFR1 levels and macrophage infiltration in liver tissue.
  • Performed macrophage-specific FGFR1 knockout and used FGFR1 inhibitors.
  • Analyzed the effects on lipid accumulation, fibrosis, and inflammatory pathways (MAPKs, TNF).

Main Results:

  • HFD increased liver p-FGFR1 levels and macrophage infiltration.
  • Macrophage-specific FGFR1 knockout or inhibition protected against HFD-induced liver damage.
  • FGFR1 inhibition suppressed MAPK/TNF signaling, reducing inflammation and fat deposition.
  • This led to decreased hepatic stellate cell activation.

Conclusions:

  • FGFR1 plays a critical role in mediating inflammatory responses in macrophages during NAFLD.
  • Targeting FGFR1 in macrophages can protect the liver from HFD-induced injury.
  • FGFR1 represents a potential therapeutic target for preventing and treating NAFLD.